10,000+ stock pitches from top investors available on joinyellowbrick.com
BAKER BROS. ADVISORS LP 13F Holdings
Holdings from the most recent 13F from BAKER BROS. ADVISORS LP
Filed: 2020-08-14 (Q2 2020) | Holdings: 114 | Value: $22.7B | Filing Link
PREMIUM
Author Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Filing Returns
Returns are calculated from when the filing is published and are weighted by the size of the holding.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Holding Returns | |||||||
|---|---|---|---|---|---|---|---|
| Stock | Put/Call | Change | Holding Pct | Value | Current Return | 3M Return | 1Y Return |
| SGEN - Seattle Genetics, Inc. | Reduce 6% $(474.2M) | 35.43% | $8.0B | +12.19% | -1.31% | ||
| INCY - Incyte Corporation | 14.67% | $3.3B | -31.73% | -11.49% | -22.36% | ||
| BGNE - BeiGene, Ltd. | 9.79% | $2.2B | +15.65% | +31.85% | +32.13% | ||
| ACAD - ACADIA Pharmaceuticals Inc. | 8.96% | $2.0B | -45.63% | +37.71% | -57.55% | ||
| ALXN - Alexion Pharmaceuticals, Inc. | 4.34% | $983.3M | +24.14% | ||||
| BMRN - BioMarin Pharmaceutical Inc. | 4.13% | $936.1M | -51.30% | -35.33% | -37.01% | ||
| KOD - Kodiak Sciences Inc. | 2.76% | $626.4M | -92.89% | +137.42% | +80.22% | ||
| ASND - Ascendis Pharma A/S | 2.21% | $501.4M | +14.73% | +15.82% | -18.11% | ||
| NVTA - Invitae Corporation | Add 30% ($83.3M) | 1.58% | $359.0M | +53.14% | -15.68% | ||
| MYOK - MyoKardia, Inc. | Add 78% ($134.3M) | 1.35% | $305.7M | +125.56% | |||
| AMRN - Amarin Corporation plc | 1.05% | $238.7M | -91.54% | -31.53% | -22.77% | ||
| ARGX - argenx SE | 1.01% | $229.6M | +139.89% | +8.17% | +27.96% | ||
| IGMS - IGM Biosciences, Inc. | 1.01% | $229.5M | -97.55% | +4.23% | +38.70% | ||
| MDGL - Madrigal Pharmaceuticals, Inc. | 0.75% | $169.8M | +158.80% | +13.70% | -22.05% | ||
| MRTX - Mirati Therapeutics, Inc. | 0.71% | $161.0M | +64.94% | -0.87% | |||
| EXAS - Exact Sciences Corporation | 0.71% | $160.5M | -34.33% | +41.74% | +8.59% | ||
| NBIX - Neurocrine Biosciences, Inc. | Reduce 27% $(40.7M) | 0.49% | $110.7M | +6.22% | -19.74% | -22.14% | |
| PRNB - Principia Biopharma Inc. | Reduce 19% $(22.4M) | 0.42% | $94.5M | ||||
| FMTX - Forma Therapeutics Holdings, Inc. | New Purchase | 0.41% | $93.0M | +22.78% | -35.28% | ||
| CERS - Cerus Corporation | 0.40% | $90.5M | -81.81% | -13.32% | -15.47% | ||
| HRTX - Heron Therapeutics, Inc. | 0.39% | $88.5M | -87.84% | +18.76% | -31.18% | ||
| INSM - Insmed Incorporated | 0.37% | $83.3M | +160.97% | +37.31% | -14.33% | ||
| AXSM - Axsome Therapeutics, Inc. | Add 13% ($9.9M) | 0.37% | $83.1M | +33.11% | -5.96% | -73.14% | |
| ADCT - ADC Therapeutics SA | New Purchase | 0.35% | $79.0M | -92.25% | -14.32% | -34.51% | |
| BCEL - Atreca, Inc. | 0.33% | $75.2M | +0.73% | -61.45% | |||
| KNSA - Kiniksa Pharmaceuticals, Ltd. | 0.31% | $71.3M | +54.58% | -10.06% | -33.56% | ||
| ADAP - Adaptimmune Therapeutics plc | Add 81% ($29.9M) | 0.29% | $66.8M | -96.38% | -37.67% | -51.05% | |
| BCRX - BioCryst Pharmaceuticals, Inc. | Add 26% ($13.4M) | 0.29% | $65.6M | +149.42% | +3.25% | +254.29% | |
| DBVT - DBV Technologies S.A. | 0.28% | $64.2M | -64.47% | +5.96% | +107.66% | ||
| ZYME - Zymeworks Inc. | 0.27% | $61.6M | -61.18% | +41.34% | +8.70% | ||
| RYTM - Rhythm Pharmaceuticals, Inc. | 0.27% | $60.2M | +237.72% | +20.54% | -30.01% | ||
| NLTX - Neoleukin Therapeutics, Inc. | 0.25% | $56.4M | |||||
| CCXI - ChemoCentryx, Inc. | Add 10% ($5.0M) | 0.24% | $54.4M | +13.56% | -74.20% | ||
| ALLK - Allakos Inc. | 0.23% | $52.9M | +12.80% | -9.80% | |||
| N/A - Neurocrine Biosciences, Inc. | 0.23% | $51.1M | |||||
| AGLE - Aeglea BioTherapeutics, Inc. | New Purchase | 0.18% | $40.5M | -90.88% | +45.07% | -3.88% | |
| ASMB - Assembly Biosciences, Inc. | 0.16% | $36.0M | -94.42% | -73.39% | -83.48% | ||
| KRYS - Krystal Biotech, Inc. | Reduce 14% $(5.3M) | 0.15% | $33.9M | +194.30% | -3.71% | +26.12% | |
| PTGX - Protagonist Therapeutics, Inc. | Add 14% ($4.1M) | 0.15% | $33.8M | +203.91% | +40.59% | +206.34% | |
| MRUS - Merus N.V. | 0.14% | $32.8M | +328.02% | +4.20% | +42.75% | ||
| APLS - Apellis Pharmaceuticals, Inc. | 0.13% | $29.3M | -41.07% | +33.76% | +95.61% | ||
| AUPH - Aurinia Pharmaceuticals Inc. | 0.12% | $27.7M | -44.12% | -4.78% | +3.06% | ||
| ALKS - Alkermes plc | 0.11% | $24.2M | +66.36% | -4.60% | +50.21% | ||
| GWPH - GW Pharmaceuticals plc | Reduce 50% $(22.8M) | 0.10% | $22.7M | +12.97% | |||
| ALT - Altimmune, Inc. | New Purchase | 0.10% | $22.6M | -77.93% | -61.71% | -52.64% | |
| ADPT - Adaptive Biotechnologies Corporation | Reduce 38% $(13.6M) | 0.10% | $22.4M | -75.71% | +19.13% | -21.28% | |
| FREQ - Frequency Therapeutics, Inc. | Reduce 20% $(5.5M) | 0.10% | $22.0M | ||||
| TCDA - Tricida, Inc. | Reduce 70% $(51.6M) | 0.10% | $21.6M | -57.35% | -74.18% | ||
| NVAX - Novavax, Inc. | New Purchase | 0.09% | $20.1M | -95.07% | -39.16% | +53.90% | |
| N/A - BioMarin Pharmaceutical Inc. | 0.08% | $18.3M | |||||
| AIMT - Aimmune Therapeutics, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| RARX - Ra Pharmaceuticals, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| XNCR - Xencor, Inc. | Reduce 100% | 0.00% | $0.00 | ||||
| URGN - UroGen Pharma Ltd. | Reduce 100% | 0.00% | $0.00 | ||||
| QURE - uniQure N.V. | Reduce 100% | 0.00% | $0.00 | -85.35% | +7.98% | -29.92% | |